Treatment of type 2 diabetes and outcomes in patients with heart failure: A nested case-control study from the U.K. general practice research database

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1213-1218

  MacDonald, Michael R ^a   Eurich, Dean T ^b   Majumdar, Sumit R ^b   Lewsey, James D ^c   Bhagra, Sai ^d   Jhund, Pardeep S ^c,e   Petrie, Mark C ^a   McMurray, John J V ^e   Petrie, John R ^e   McAlister, Finlay A ^b,f  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SPIRONOLACTONE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE DURATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INSULIN TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SEX; TREATMENT OUTCOME; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIGOXIN; FEMALE; GREAT BRITAIN; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN;

EID: 77956074249     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2227     Document Type: Article

References (22)

1. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007;99(Suppl.): 113B-132B
2. Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J AmColl Cardiol 2007;49:1696-1704 (Pubitemid 46589926)
3. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497-507
4. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200-206
5. Gelfand JM, Margolis DJ, Dattani J. The UK General Practice Research Database. In Pharmacoepidemiology. 4th ed. Strom BL, Ed. London, John Wiley & Sons, 2005, p. 337-346
6. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5
7. Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005;28:20-26 (Pubitemid 40095777)
8. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 2004;364:423-428
9. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
10. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-1026
11. Suskin N, McKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-1375
12. Saccà L, Napoli R. Insulin resistance in chronic heart failure: a difficult bull to take by the horns. Nutr Metab Cardiovasc Dis 2009;19:303-305
13. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51:93-102
14. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S, CHARM Program Investigators. The hemoglobin A1C level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008;168:1699-1704
15. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1C levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91
16. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J AmColl Cardiol 2009;54:422-428
17. Montori VM, Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803-808
18. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-1538
19. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials Am Heart J 2003;146:848-53
20. McAlister FA. Applying evidence to patient care: from black and white to shades of grey. Ann Intern Med 2003;138:938-9
21. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147(6):386-99
22. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168(19):2070-80